Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — Q1 2026 Earnings Presentation
20 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2026
Slide 1: 1Q2026 Company Update
1Q2026 Company Update PT Prodia Widyahusada Tbk | PRDA.JK
Slide 2: Disclaimer
This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By viewing all or
Slide 3: Company Overview
Company Overview
Slide 4: 1Q2026 Key Highlights
1Q2026 Key Highlights Key Player in Private Independent Clinical Lab chain with 40.0%* market share in Indonesia Start from 2025, Prodia expands networks through strategic Current Initiatives collaboration in SEA Market and optimalization of clinical IDR 501.3 Billion services USD 29.5 Million Feb 2
Slide 5: Continuous Improvement in a Challenging Market
Continuous Improvement in a Challenging Market Ensure sustainability business with innovation, growth, and optimization Visits Revenue (in Million) (in IDR Trillion) CAGR* CAGR >3.0 * 2.3 -1.8% 4.0% >2.7 1.9 Prodia has strengthen the fundamental and generated continuous 2020 2021 2022 2023 2024 2025
Slide 6: Business Highlight
Business Highlight
Slide 7: The Comprehensive Center of Excellence
The Comprehensive Center of Excellence Delivering personalization and precision in multiple customer segments Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, Multiomics General Medical Preventive Treatment offering th
Slide 8: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model Centralized core operations (hub) while efficiently distributing services through multiple outlets (spokes) 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved Centralized information with Prodia Clinical Labs, Hospitals
Slide 9: Maintain Strong and Long-Term Relationship
Maintain Strong and Long-Term Relationship Generate new tests and ongoing referrals in partnership with medical & scientific community Strong relationships through the work of Introduced new tests, such as HPV-DNA High Risk Self- more than 500 Marketing and Collection (My HPV Test), Maternal Cell Co
Slide 10: Be The Next Generation Laboratory
Be The Next Generation Laboratory To deliver precision medicine with comprehensive lab services Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Predictive & Separation Science Diagnostic Laboratory Laboratory Next Generation Laboratory Anatomical Pathology Cancer Molecular La
Slide 11: Business Updates
Business Updates
Slide 12: Expand Our Presence with Diverse Models
Expand Our Presence with Diverse Models With strategic expansion of outlets, ensuring proximity to our customers FY2025 1Q2026 Digital Platform Optimization 2026 Outlet Development Target >3 Hospital Labs Management 402 395 Outlets Outlets includes hospital lab & genomic site U by Prodia > 20 POC Ou
Slide 13: Financial Updates
Financial Updates
Slide 14: Excellent Performance in 1Q2026 Revenue
Excellent Performance in 1Q2026 Revenue Supported by broad-based growth across segments Revenue (Unaudited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion 1Q21-1Q26 CAGR -4.3% 2021 2022 2023 2024 2025 2026 626 1Q25-1Q26 556 Growth: +3.8% 518 1Q2026 revenue reached 487 483 501 the highes
Slide 15: 1Q2026 Financial Performance
1Q2026 Financial Performance Margins impacted by higher COGS, while revenue growth remains solid COGS Gross Profit OPEX Net Income in IDR Billion in IDR Billion In IDR Billion In IDR Billion 1Q21-1Q26 CAGR -0.6% 1Q21-1Q26 CAGR -6.9% 1Q21-1Q26 CAGR +5.4% 1Q21-1Q26 CAGR -35.9% COGS to revenue Gross Pr
Slide 16: 1Q2026 Financial Summary
1Q2026 Financial Summary 1Q2026 Financial Performance was excellent compare to previous year (in IDR Bn) 1Q2026 1Q2025 Change (in IDR Bn) 1Q2026 1Q2025 Change Revenue 501.4 483.0 +3.8% Total Asset 2,675.0 2,806.2 -4.7% 263.5 Total Equity 2,411.6 2,496.6 -3.4% Gross Profit 272.1 +3.3% EBIT 18.0 -1.4
Slide 17: Professional Team & Shares Information
Professional Team & Shares Information
Slide 18: Experienced & Professional Management Team
Experienced & Professional Management Team With more than 20 years experience in delivering growth and innovation of Prodia Years of 54 Experience 35 Years of 43 Years of Experience 38 Years of Experience Experience Years of 54 Years of 39 Experience Experience Gunawan Endang Keri KeriLestari Lestar
Slide 19: Shareholders Composition
Shareholders Composition Public free float is 26% of total with market cap of IDR 2.40 Trillion* PT Prodia Utama Bio Majesty Pte. Ltd. Public Treasury Stock 57% 12% 26% 5% 30% Distributor for Contract Research Research, therapy and medical Organization banking of stem cell equipment PT Prodia Widyah
Slide 20: For further Information
For further Information: PT Prodia Widyahusada Tbk Prodia Tower, Jalan Kramat Raya No. 150 Jakarta 10430, Indonesia Email: investor.relation@prodia.co.id
PT Prodia Widyahusada — Q1 2026 Earnings Presentation on 6ix